Another meta-analysis study that incorporated 509 patients (138 of KRAS-mutant and 371 with KRAS-wild-type NSCLC) showed that, compared to docetaxel chemotherapy, immune checkpoint inhibitors improved overall survival in patients with previously-treated KRAS-mutant NSCLC (HR = 0.64 [95% confidence interval, 0.43–0.96], P = 0.03) (99), but not in patients with wild-type KRAS (HR = 0.88 [95% confidence interval, 0.68–1.13], P = 0.30). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.